EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

Immune Checkpoint Inhibitor-Related Bullous Pemphigoid with Negative Direct Immunofluorescence during Pembrolizumab Plus Lenvatinib Therapy: A Case Report

Ayane Seko, Shimpei Nagai, Makiko Hino, Noriko Takatsuji, Terumi Shirane, Moito Iijima, Yoshihisa Hattori, Takashi Kurahashi

Case Reports in Dermatology · 09.10.2026 · 18 (1) · 785-792

DOI: 10.1159/cde/abvag021 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Case Reports in Dermatology, online erschienen am 09.10.2026. Verfasst von Ayane Seko und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, National Hospital Organization Saitama Hospital, Saitama, Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction: Bullous pemphigoid (BP) is a rare but clinically significant cutaneous immune-related adverse event (irAE) of immune checkpoint inhibitor (ICI) therapy. It is most often described during treatment of melanoma, lung cancer, and renal cell carcinoma, whereas reports in gynecologic oncology, and specifically during lenvatinib plus pembrolizumab (LP) therapy, remain scarce. Case Presentation: A 53-year-old Japanese woman with International Federation of Gynecology and Obstetrics (FIGO) stage IA endometrioid carcinoma underwent hysterectomy followed by adjuvant paclitaxel-carboplatin. Peritoneal recurrence occurred 30 months later. After paclitaxel-carboplatin rechallenge and subsequent progression, LP therapy was initiated. At 38 weeks (cycle 9), erythema progressed to widespread tense bullae on the trunk and extremities with hard-palate erosion. Serum anti-BP180 antibody was markedly elevated (115.4 U/mL; reference:

Schlagwörter

Stichwörter der Autor:innen

Bullous pemphigoidEndometrial carcinomaImmune checkpoint inhibitorImmune-related adverse eventPembrolizumab

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, National Hospital Organization Saitama Hospital, Saitama, Japan.
  • Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.

Zitieren

APA

Seko, A., Nagai, S., Hino, M., Takatsuji, N., Shirane, T., Iijima, M., Hattori, Y., & Kurahashi, T. (2026). Immune Checkpoint Inhibitor-Related Bullous Pemphigoid with Negative Direct Immunofluorescence during Pembrolizumab Plus Lenvatinib Therapy: A Case Report. Case Reports in Dermatology, 18(1), 785-792. https://doi.org/10.1159/cde/abvag021

Vancouver

Seko A, Nagai S, Hino M, Takatsuji N, Shirane T, Iijima M, et al. Immune Checkpoint Inhibitor-Related Bullous Pemphigoid with Negative Direct Immunofluorescence during Pembrolizumab Plus Lenvatinib Therapy: A Case Report. Case Reports in Dermatology. 2026;18(1):785-792. doi:10.1159/cde/abvag021

BibTeX
@article{Seko2026,
  author = {Seko, Ayane and Nagai, Shimpei and Hino, Makiko and Takatsuji, Noriko and Shirane, Terumi and Iijima, Moito and Hattori, Yoshihisa and Kurahashi, Takashi},
  title = {Immune Checkpoint Inhibitor-Related Bullous Pemphigoid with Negative Direct Immunofluorescence during Pembrolizumab Plus Lenvatinib Therapy: A Case Report},
  journal = {Case Reports in Dermatology},
  year = {2026},
  volume = {18},
  number = {1},
  pages = {785--792},
  doi = {10.1159/cde/abvag021}
}
Kostenlos starten →